Abstract 55P
Background
Epidermal Growth Factor Receptor (EGFR) represents one of the main molecular druggable targets in non-small-cell lung cancer (NSCLC). Osimertinib is an irreversible EGFR-tyrosine kinase inhibitor currently recognised as the standard of care for first-line treatment of EGFR-positive patients with common mutations (L858R or ex19del). Next Generation Sequencing (NGS) is recommended for routine use to detect gene mutation in NSCLC; moreover, NGS can quantitate the proportion of mutant variant reads for each mutation, the variant allele frequency (VAF). EGFR-VAF determined by liquid biopsy is known to be a prognostic factor in NSCLC patients. The role of EGFR-VAF determined on histological specimen in patients receiving first-line osimertinib is unclear.
Methods
From February 2019 to April 2023 a cohort of 68 patients with diagnosis of advanced EGFR mutated NSCLC started first-line osimertinib at San Raffaele Hospital, in Milan (Italy). We excluded from our analysis patients with VAF value unavailable (n=20). VAF was determined by NGS in pre-treatment baseline tissue samples.
Results
48 NSCLC patients were included in our analysis. Median EGFR-VAF was 31%, mean 35.9%, first quartile 17%, third quartile 52%. Cut-off of 50% was established to distinguish patients in high-VAF group (hVAF) and low-VAF (lVAF). Applying Log Rank test progression-free survival (PFS) was significantly shorter in hVAF patients [HR 0,30 (95% CI 0.12-0.8, p = 0.01)] than in lVAF group. With the limits of a 14.9 months median follow up, overall survival was significantly shorter in patients with high VAF [HR 0.19 (95% CI 0.056-0.648, p = 0.003)]. No correlation with other features (age, sex, smoke status, metastatic sites, PD-L1 expression) was found in covariate analysis, except for the mutation site L858R or ex19del, the latter being more frequently associated with hVAF.
Conclusions
High EGFR VAF on tissue seems to be predictive of a reduced response to osimertinib in NSCLC. Our findings must be validated on a greater number of cases, and a longer follow up is needed to confirm the correlation with shorter overall survival.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
S.T. Riva.
Funding
Has not received any funding.
Disclosure
R. Ferrara: Financial Interests, Personal, Advisory Board, In April 2022: MSD; Financial Interests, Personal, Advisory Board: Beigene; Financial Interests, Institutional, Invited Speaker: MSD, Pfizer, AstraZeneca, Roche, Sanofi, Novartis, BMS, Ipsen, Daiichi Sankyo Company. S. Pilotto: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, AstraZeneca, MSD, Roche, Amgen, Novartis, Takeda, Sanofi; Financial Interests, Personal, Advisory Board: MSD, Amgen, AstraZeneca, Novartis, Eli Lilly, Sanofi; Financial Interests, Personal, Research Grant: Bristol Myers Squibb, AstraZeneca; Non-Financial Interests, Personal, Principal Investigator: AstraZeneca, Roche, BMS. A. Bulotta: Financial Interests, Personal, Advisory Board: Roche, BMS, AstraZeneca; Financial Interests, Institutional, Invited Speaker: BMS, MSD, AstraZeneca, Eli Lilly. M. Reni: Financial Interests, Personal, Advisory Board: Celgene, Eli Lilly, Pfizer, Baxalta, Shire, Novocure, Novartis, Boston Biomedicals; Non-Financial Interests, Institutional, Principal Investigator: Celgene. M. Milella: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Pfizer, Merck-Serono, Novartis, Ipsen, Viatris; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Institutional, Funding: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
51P - Functional characterization of the novel long intergenic non-coding RNA-RFC4, a transcript regulating chromosomal instability in prostate cancer
Presenter: Rogelio Montiel Manríquez
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Heterogeneous characteristics of KRAS mutation subtypes in surgically resected lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - ATRX-deficient IDH-wildtype adult high-grade gliomas display novel, clinically relevant genetic patterns by comprehensive genomic profiling
Presenter: Gábor Bedics
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Clinical characteristics and outcomes in non-small cell lung cancer (NSCLC) with tumour and germline BRCA1/2 mutations
Presenter: Greydon Arthur
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Molecular investigation using microarray-based comparative genomic hybridization in patients with myelodysplastic syndrome and normal karyotype
Presenter: Mohamed abd naceur AMMAR
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Unraveling methylation signatures in RAS/BRAF wild-type colorectal cancer patients to identify predictive biomarkers for anti-epidermal growth factor receptor therapy
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - Spindle cell sarcomas with tyrosine kinase rearrangement
Presenter: Lenka Krsková
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
Presenter: Ioanna Mavrommatis
Session: Cocktail & Poster Display session
Resources:
Abstract
62P - Role of IL6 (C-174G) polymorphism in the development of cervical intraepithelial neoplasia
Presenter: Tatyana Abakumova
Session: Cocktail & Poster Display session
Resources:
Abstract